Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
|
Digimarc CORP (Name of Issuer) |
Common Stock, par value $0.001 per share (Title of Class of Securities) |
25381B101 (CUSIP Number) |
Riley McCormack 8500 SW CREEKSIDE PLACE, BEAVERTON, OR, 97008 (305) 631-2754 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
03/17/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 25381B101 |
| 1 |
Name of reporting person
TCM Strategic Partners L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,355,093.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
10.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 25381B101 |
| 1 |
Name of reporting person
TCM Strategic GP LLC | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,355,093.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
10.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
HC, OO |
SCHEDULE 13D
|
| CUSIP No. | 25381B101 |
| 1 |
Name of reporting person
mccormack riley | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
AF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
2,451,833.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
11.4 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN, HC |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.001 per share | |
| (b) | Name of Issuer:
Digimarc CORP | |
| (c) | Address of Issuer's Principal Executive Offices:
8500 SW CREEKSIDE PLACE, BEAVERTON,
OREGON
, 97008. | |
Item 1 Comment:
This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") amends and supplements the Schedule 13D filed on October 5, 2020, as amended by Amendment No. 1 filed on December 16, 2020 (collectively, the "Schedule 13D") by the Reporting Persons (as defined below), relating to the shares of common stock, par value $0.001 per share ("Common Stock"), of Digimarc Corporation (the "Issuer" or the "Company"). Each Item below amends and supplements the information disclosed under the corresponding Item of the Schedule 13D. Except as specifically provided herein, this Amendment No. 2 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 2 shall have the same meaning given to such terms in the Schedule 13D. | ||
| Item 2. | Identity and Background | |
| (b) | Item 2(b) of the Schedule 13D is hereby amended and restated in its entirety as follows: The principal business address of each Reporting Person is 8500 SW CREEKSIDE PLACE, BEAVERTON, OREGON 97008. | |
| Item 3. | Source and Amount of Funds or Other Consideration | |
Item 3 of the Schedule 13D is hereby amended and supplemented by the following: Mr. McCormack was granted 8,644 shares of restricted stock on April 12, 2021, in connection with his appointment as President and Chief Executive Officer of the Issuer, and since then has received restricted stock units ("RSUs") upon attainment of certain performance goals representing the contingent right to receive an aggregate 19,469 shares of Common Stock in connection with his service as President and Chief Executive Officer of the Issuer. Between March 8 and March 9, 2022, Mr. McCormack purchased an aggregate 30,000 shares of Common Stock for an aggregate purchase price of $732,459.75, using his personal funds. | ||
| Item 4. | Purpose of Transaction | |
Item 4 of the Schedule 13D is hereby amended and supplemented by the following: On March 17, 2025, TCM Partners made an in-kind distribution of an aggregate 1,385,147 shares of Common Stock to certain of its limited partners on a proportionate basis, for no consideration, including 32,081 shares that were distributed to TCM Strategic L.P., an entity wholly owned by Mr. McCormack. Since the filing of Amendment No. 1, on April 12, 2021, Mr. McCormack was appointed as President and Chief Executive Officer of the Issuer. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Item 5(a) of the Schedule 13D is hereby amended and restated in its entirety as follows: As of the date hereof, each of TCM Partners and TCM GP may be deemed to beneficially own 2,355,093 shares of Common Stock directly owned by TCM Partners as the holder of record, representing approximately 10.9% of the shares of Common Stock outstanding, and Mr. McCormack may be deemed to beneficially own 2,451,833 shares of Common Stock, representing approximately 11.4% of the shares of Common Stock outstanding. The percentages set forth herein are calculated based on 21,548,579 shares of Common Stock outstanding as of February 21, 2025, as set forth in the Company's annual report on Form 10-K filed on February 27, 2025, plus approximately 19,137 shares of unvested restricted Common Stock or unvested RSUs issued to Mr. McCormack, which have been added to the total quantity of shares of Common Stock outstanding in accordance with Rule 13d-3(d)(1)(i) under the Act, for a total of 21,567,716 shares of Common Stock outstanding. | |
| (b) | Item 5(b) of the Schedule 13D is hereby amended and restated in its entirety as follows: As of the date hereof, each of the Reporting Persons may be deemed to have shared power to vote or to direct the vote, and shared power to dispose or to direct the disposition, of the 2,355,093 shares of Common Stock directly owned by TCM Partners as the holder of record. As of the date hereof, Mr. McCormack may be deemed to have sole power to vote or to direct the vote, and sole power to dispose or to direct the disposition, of the 96,740 shares of Common Stock directly owned by him and by TCM Strategic L.P. | |
| (c) | Item 5(c) of the Schedule 13D is hereby amended and restated in its entirety as follows: The response to Item 4 of this Amendment No. 2 is hereby incorporated by reference herein. Also, on February 15, 2025, Mr. McCormack was granted RSUs upon attainment of certain performance goals representing the contingent right to receive 18,160 shares of Common Stock in connection with his service as President and Chief Executive Officer of the Issuer. Other than as set forth herein, no transactions in the Company's securities have been effected by the Reporting Persons during the past 60 days. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|